Review




Structured Review

MultiTarget Pharmaceuticals midostaurin
Molecular structure of <t>midostaurin.</t>
Midostaurin, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/midostaurin/pmc07001097-32-0-3
Average 90 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis"

Article Title: European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

Journal: ESMO Open

doi: 10.1136/esmoopen-2019-000606

Molecular structure of midostaurin.
Figure Legend Snippet: Molecular structure of midostaurin.

Techniques Used:

Key favourable and unfavourable effects for  midostaurin  in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy and for patients in complete response followed by  midostaurin  single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation positive (study A2301; cut-off date: 1 April 2015)
Figure Legend Snippet: Key favourable and unfavourable effects for midostaurin in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy and for patients in complete response followed by midostaurin single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation positive (study A2301; cut-off date: 1 April 2015)

Techniques Used: Mutagenesis, Infection

Effects table for  midostaurin  in adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL) (study D2201; cut-off date: 1 December 2014)
Figure Legend Snippet: Effects table for midostaurin in adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL) (study D2201; cut-off date: 1 December 2014)

Techniques Used: Modification

Related Articles

Activation Assay:

Article Title: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
Article Snippet: Great successes have been achieved in developing small-molecule kinase inhibitors as anticancer therapeutic agents.. However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.. Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria.

Injection:

Article Title: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
Article Snippet: Great successes have been achieved in developing small-molecule kinase inhibitors as anticancer therapeutic agents.. However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.. Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria.

Inhibition:

Article Title: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
Article Snippet: Great successes have been achieved in developing small-molecule kinase inhibitors as anticancer therapeutic agents.. However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.. Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria.

Mutagenesis:

Article Title: Cardiac complications in a patient affected by systemic mastocytosis and primitive myelofibrosis: A case report
Article Snippet: .. The more recent drug approved for the SM‐AHNMD is midostaurin, a multitarget inhibitor active against KIT D816V mutation, approved in 2017 by FDA and EMA after two open label II phase studies. ..

Article Title: Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.
Article Snippet: Here, we discover an FLT3/CHK1 dual inhibitor (30) that exhibits excellent kinase potency and antiproliferative activity against MV4-11 cells.. Simultaneously, 30 possesses high selectivity over c-Kit enzyme and low hERG inhibitory ability.. Compound 30, meanwhile, overcomes varied resistance in BaF3 cell lines carrying FLT3-TKD and FLT3-ITD mutations.

other:

Article Title: Effect of flavonoids and CYP3A4 variants on midostaurin metabolism.
Article Snippet: The objective of this study was to determine the effect of flavonoids on midostaurin disposition considering coadministration and metabolic enzyme gene polymorphism.. Enzymatic incubation assays were performed in vitro, while in vivo experiments were conducted in Sprague–Dawley rats.. The analytes were determined via UPLC-MS/ MS. We found that myricetin was the most potent among the investigated 10 flavonoids in suppressing the metabolism of midostaurin, with an IC50 at a low μM level.

Article Title: Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment
Article Snippet: Introduction: Whereas most patients with aggressive hematological malignancies can achieve disease remission after receiving current standard first-line chemotherapies, the prognosis of those with primary refractory disease remains poor.. Conventional salvage chemotherapies are usually unsuccessful, but significant advances have been achieved in precision medicine for these patients in recent years.. Areas covered: This article presents a comprehensive review of current personalized care for patients with primary refractory aggressive hematological malignancies, focusing on acute leukemias and aggressive non-Hodgkin lymphomas.



Similar Products

94
TargetMol midostaurin
Midostaurin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/Midostaurin/pm42486263-266-27-32
Average 94 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
MedChemExpress pkc412
Pkc412, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/Midostaurin/pm41589658-312-7-11
Average 94 stars, based on 1 article reviews
pkc412 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
MedChemExpress pkc flt3 midostaurin
Pkc Flt3 Midostaurin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/Midostaurin/pmc13091335-23-27-44
Average 94 stars, based on 1 article reviews
pkc flt3 midostaurin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Novartis midostaurin
Midostaurin, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/midostaurin/us12551564-1110-146-148
Average 86 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Mastocytosis Society midostaurin rydapt 2017
Midostaurin Rydapt 2017, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/2017+midostaurin+rydapt/10__3390_slash_targets4010004-127-0-14
Average 86 stars, based on 1 article reviews
midostaurin rydapt 2017 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Selleck Chemicals midostaurin
(A) Schematic overview of the organelle proteomics pipeline. FLT3 ITD-JMD (TKI-sensitive) and FLT3 ITD-TKD (TKI-resistant) Ba/F3 cells were left untreated or treated with 100 nM <t>midostaurin</t> for 24 h. Sequential extraction with six buffers generated six subcellular fractions, which were analyzed by MS-based proteomics in biological quadruplicates. Peptides were subjected to global proteomic profiling and phosphopeptide enrichment. (B) Intensity profiles of organelle-specific marker proteins across the six fractions. (C) Hierarchical clustering of protein profiles (scaled intensities) across fractions for untreated and midostaurin-treated FLT3-ITD cells. Statistically significant enriched gene ontology terms in each cluster are indicated.
Midostaurin, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/midostaurin/Midostaurin/bio_rxiv__64898__2026__01__19__700272-25-0-1
Average 93 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


(A) Schematic overview of the organelle proteomics pipeline. FLT3 ITD-JMD (TKI-sensitive) and FLT3 ITD-TKD (TKI-resistant) Ba/F3 cells were left untreated or treated with 100 nM midostaurin for 24 h. Sequential extraction with six buffers generated six subcellular fractions, which were analyzed by MS-based proteomics in biological quadruplicates. Peptides were subjected to global proteomic profiling and phosphopeptide enrichment. (B) Intensity profiles of organelle-specific marker proteins across the six fractions. (C) Hierarchical clustering of protein profiles (scaled intensities) across fractions for untreated and midostaurin-treated FLT3-ITD cells. Statistically significant enriched gene ontology terms in each cluster are indicated.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Schematic overview of the organelle proteomics pipeline. FLT3 ITD-JMD (TKI-sensitive) and FLT3 ITD-TKD (TKI-resistant) Ba/F3 cells were left untreated or treated with 100 nM midostaurin for 24 h. Sequential extraction with six buffers generated six subcellular fractions, which were analyzed by MS-based proteomics in biological quadruplicates. Peptides were subjected to global proteomic profiling and phosphopeptide enrichment. (B) Intensity profiles of organelle-specific marker proteins across the six fractions. (C) Hierarchical clustering of protein profiles (scaled intensities) across fractions for untreated and midostaurin-treated FLT3-ITD cells. Statistically significant enriched gene ontology terms in each cluster are indicated.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Extraction, Generated, Phospho-proteomics, Marker

(A) Schematic representation of the bioinformatic strategy used to assign a cell compartment to proteins by using the SVM-algorithm. (B) Number of proteins assigned to cytosolic, nuclear, or organellar compartments in untreated and midostaurin treated FLT3-ITD cells. (C) Quantification of proteins changing their subcellular localization upon midostaurin treatment. (D) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-JMD . (E) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-JMD . (F) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-TKD cells. (G) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-TKD cells.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Schematic representation of the bioinformatic strategy used to assign a cell compartment to proteins by using the SVM-algorithm. (B) Number of proteins assigned to cytosolic, nuclear, or organellar compartments in untreated and midostaurin treated FLT3-ITD cells. (C) Quantification of proteins changing their subcellular localization upon midostaurin treatment. (D) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-JMD . (E) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-JMD . (F) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-TKD cells. (G) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-TKD cells.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Translocation Assay, Functional Assay

Bar plots reporting the -log2 (p-value) of the GO-Term enrichment analysis of translocating proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (C) Schematic representation of the spatial remodelling of key autophagic proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (D) Heatmap reporting the intensity of the phosphorylation level of translocating autophagic proteins after midostaurin treatment in FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Western blotting of LC3-II and p62 protein levels in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with midostaurin with or without bafilomycin A1 for 24 hours. (F) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with 3 hours of starvation.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: Bar plots reporting the -log2 (p-value) of the GO-Term enrichment analysis of translocating proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (C) Schematic representation of the spatial remodelling of key autophagic proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (D) Heatmap reporting the intensity of the phosphorylation level of translocating autophagic proteins after midostaurin treatment in FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Western blotting of LC3-II and p62 protein levels in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with midostaurin with or without bafilomycin A1 for 24 hours. (F) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with 3 hours of starvation.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Phospho-proteomics, Western Blot, MTT Assay

(A) Bar plot reporting the ECAR based measurements of glycolysis and glycolytic capacity in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a glycolysis stress test. ( B ) OCR-derived assessments of basal respiration and ATP production in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a mitochondrial stress test. (C) Representative electron microscopy images of steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells (m=mitochondria). (D) Bar plots reporting the number of cristae, the total cristae area and total mitochondria area in steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells. (E) Intensity profiles of the 168 proteins annotated in the MitoCarta database as mitochondrial proteins across the six fractions in each experimental condition. Colored boxes indicate the enriched GO-Term biological processes and cell compartments. (F) Heatmaps reporting the protein levels (scaled intensities) of the OXPHOS related proteins across the 6 fractions in each experimental condition.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Bar plot reporting the ECAR based measurements of glycolysis and glycolytic capacity in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a glycolysis stress test. ( B ) OCR-derived assessments of basal respiration and ATP production in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a mitochondrial stress test. (C) Representative electron microscopy images of steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells (m=mitochondria). (D) Bar plots reporting the number of cristae, the total cristae area and total mitochondria area in steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells. (E) Intensity profiles of the 168 proteins annotated in the MitoCarta database as mitochondrial proteins across the six fractions in each experimental condition. Colored boxes indicate the enriched GO-Term biological processes and cell compartments. (F) Heatmaps reporting the protein levels (scaled intensities) of the OXPHOS related proteins across the 6 fractions in each experimental condition.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Derivative Assay, Electron Microscopy

(A) Heatmap reporting the number of translocating proteins involved in carbohydrate, amino acids, peroxisome and lipid metabolism in FLT3 ITD-JMD and FLT3 ITD-TKD . (B) Bar plot reporting the ΔOCR of basal respiration after the inhibition of glucose usage (UK5099), glutamine usage (BPTES) and lipid usage (ETOMOXIR) for OXPHOS in FLT3 ITD-JMD and FLT3 ITD-TKD in absence and presence of 100nM midostaurin treatment for 24h. (C) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with glucose, amino acid and lipid deprivation. (D) Representative immunofluorescence images of FLT3 localization before and after lipid deprivation in both permeabilized and non-permealized FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Barplots showing the percentage of treatment-induced apoptosis (100 * (dead cells after treatment – death cells in control) / viable cells in control) in patient-derived blasts carrying FLT3-ITD in i) the JM domain, ii) both the JM and TK domain and iii) the TK domain upon the indicated treatments. Percentage of apoptotic cells was assessed by Annexin-V labeling.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Heatmap reporting the number of translocating proteins involved in carbohydrate, amino acids, peroxisome and lipid metabolism in FLT3 ITD-JMD and FLT3 ITD-TKD . (B) Bar plot reporting the ΔOCR of basal respiration after the inhibition of glucose usage (UK5099), glutamine usage (BPTES) and lipid usage (ETOMOXIR) for OXPHOS in FLT3 ITD-JMD and FLT3 ITD-TKD in absence and presence of 100nM midostaurin treatment for 24h. (C) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with glucose, amino acid and lipid deprivation. (D) Representative immunofluorescence images of FLT3 localization before and after lipid deprivation in both permeabilized and non-permealized FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Barplots showing the percentage of treatment-induced apoptosis (100 * (dead cells after treatment – death cells in control) / viable cells in control) in patient-derived blasts carrying FLT3-ITD in i) the JM domain, ii) both the JM and TK domain and iii) the TK domain upon the indicated treatments. Percentage of apoptotic cells was assessed by Annexin-V labeling.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Inhibition, MTT Assay, Immunofluorescence, Control, Derivative Assay, Labeling